Seliger SL, Gitomer B, You Z, et al. Empagliflozin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial. J Am Soc Nephrol, 2026

PMID 42925875

Pilot RCT, 50 adults 18-55 with high-risk ADPKD not on tolvaptan, empagliflozin vs placebo 12 months. Tolerated by 96% in each arm; htTKV growth 10.5%/yr vs 5.1%/yr (P=0.001); no difference in eGFR slope months 1-12.